Skip to main content

Table 2 Patient demographics and sample information

From: Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

 

Group A (N = 14)

Group B (N = 67)

Total (N = 81)

Type of specimen

Frozen plasma

Fresh whole blood

All samples

Age: median (range)

68 (44–73)

67 (45–93)

67 (44–93)

Gender: female N (%)

9 (64%)

46 (69%)

55 (68%)

Race/ethnicity: N (%)

 Caucasian

8 (57%)

43 (64%)

51 (63%)

 Asian

2 (14%)

13 (19%)

15 (19%)

 Hispanic

2 (14%)

6 (9%)

8 (10%)

 African American

2 (14%)

5 (7%)

7 (9%)

Cancer type/histology: N (%)

 LUAD

2 (14%)

40 (60%)

42 (52%)

 LUSC

9 (64%)

8 (12%)

17 (21%)

 Breast

3 (21%)

13 (19%)

16 (20%)

 Other cancer types*

0

6 (9%)

6 (7%)

  1. *Other cancer types include lung small cell carcinoma (n = 2); lung large cell neuroendocrine (n = 1); ovarian, adenocarcinoma (n = 2); prostate, adenocarcinoma (n = 1)
  2. LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma